Gene Therapy Grows Up as US Manufacturing Hits Its Stride

A North Carolina facility acquisition highlights a shift toward commercial gene therapy manufacturing as developers seek to reduce supply risks

3 Feb 2026

The effort to scale gene therapies in the United States is entering a more operational phase, as manufacturers move to expand capacity for commercial production. A recent acquisition in North Carolina underscores how the viral vector sector is shifting from research-driven growth toward execution at scale.

Oxford Biomedica, a London-listed company, has acquired a ready-to-use viral vector manufacturing facility from National Resilience. According to company statements, the site has regulatory clearance for manufacturing and is expected to begin operations in early 2026, supporting larger production volumes as gene therapies advance toward broader patient use. For an industry long constrained by limited supply, the move points to an effort to address bottlenecks that have complicated development timelines and commercialization plans.

Viral vectors are central to gene therapies, serving as delivery vehicles for genetic material into patient cells. Early-stage clinical programs can often rely on small, customized batches. Commercial therapies, by contrast, require consistent, large-scale production under strict regulatory oversight. Analysts have warned that U.S. manufacturing capacity has struggled to keep pace with the growing number of late-stage gene therapy programs, increasing risks tied to cost, delays and access.

By acquiring an existing facility rather than building one, Oxford Biomedica appears to be emphasizing speed and predictability. Company executives have pointed to the value of operating closer to U.S.-based customers and regulators, particularly as developers seek to shorten supply chains and limit operational uncertainty. The site’s location within an established biotechnology corridor also provides access to a specialized workforce and supporting infrastructure.

The transaction reflects broader activity across the life sciences sector. Large service providers, including Thermo Fisher, have been expanding manufacturing capacity in the United States, a signal, analysts said, of confidence in sustained demand for gene therapies. At the same time, companies like National Resilience are reshaping their portfolios, divesting certain assets while keeping them active within the broader ecosystem.

Obstacles persist. Regulatory standards continue to evolve, raising costs and complexity, and competition for experienced manufacturing talent remains intense. Still, industry observers generally view those challenges as more manageable than the long-term risk of insufficient capacity.

As more gene therapies approach regulatory decisions, the viral vector market is becoming less defined by experimental promise and more by execution. How quickly and reliably companies can scale production may help shape the next phase of gene therapy delivery in the United States.